Avasarala, Jagannadha. 2017. “Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab Is Overkill”. Drug Target Insights 11 (1). https://doi.org/10.33393/dti.2017.1367.